Syncona-backed OMass Therapeutics raises $310 million in series C financing
LONDON: OMass Therapeutics, a biotechnology company developing small molecule drugs for rare diseases and immunological conditions, has raised $310 million in an oversubscribed Series C financing, its investor Syncona Ltd. announced Thursday. Syncona, a life science investment firm, said it…